Compare Neurocrine Biosciences Inc (NBIX) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Teladoc Health Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Teladoc Health Inc trades at $6.1 (market cap $1.14B). The key difference: Neurocrine Biosciences Inc is far larger — about 13.8× Teladoc Health Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TDOC | |
|---|---|---|
Market Cap | $15.77B | $1.14B |
Sector | Health | Health |
52-Week High | $185.50 | $9.72 |
52-Week Low | $123.10 | $4.47 |
Enterprise Value | $15.78B | $1.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Recent news includes the appointment of a new CFO and ongoing legal investigations, while analyst consensus is a $8.88 price target with a hold-heavy rating.
The outlook is mixed: valuation metrics like P/S of 0.45 and EV/EBITDA of 6.5 suggest potential undervaluation, but persistent losses and negative cash flow in 2025 pose risks. Upside hinges on profitability improvements from its integrated care segment, while competitive pressures and weak BetterHelp performance are headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
